Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside Inhibitors
Open Access
- 1 March 2002
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 46 (3) , 731-738
- https://doi.org/10.1128/aac.46.3.731-738.2002
Abstract
Previous data have indicated that the development of resistance to amprenavir, an inhibitor of the human immunodeficiency virus type 1 protease, is associated with the substitution of valine for isoleucine at residue 50 (I50V) in the viral protease. We present further findings from retrospective genotypic and phenotypic analyses of plasma samples from protease inhibitor-naïve and nucleoside reverse transcriptase inhibitor (NRTI)-experienced patients who experienced virological failure while participating in a clinical trial where they had been randomized to receive either amprenavir or indinavir in combination with NRTIs. Paired baseline and on-therapy isolates from 31 of 48 (65%) amprenavir-treated patients analyzed demonstrated the selection of protease mutations. These mutations fell into four distinct categories, characterized by the presence of either I50V, I54L/I54M, I84V, or V32I+I47V and often included accessory mutations, commonly M46I/L. The I50V and I84V genotypes displayed the greatest reductions in susceptibility to amprenavir, although each of the amprenavir-selected genotypes conferred little or no cross-resistance to other protease inhibitors. There was a significant association, for both amprenavir and indinavir, between preexisting baseline resistance to NRTIs subsequently received during the study and development of protease mutations ( P = 0.014 and P = 0.031, respectively). Our data provide a comprehensive analysis of the mechanisms by which amprenavir resistance develops during clinical use and present evidence that resistance to concomitant agents in the treatment regimen predisposes to the development of mutations associated with protease inhibitor resistance and treatment failure.Keywords
This publication has 26 references indexed in Scilit:
- HIV Type 1 Protease Cleavage Site Mutations and Viral Fitness: Implications for Drug Susceptibility Phenotyping AssaysAIDS Research and Human Retroviruses, 2000
- Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studiesAIDS, 2000
- The HIV Type 1 Protease Inhibitor Saquinavir Can Select for Multiple Mutations that Confer Increasing ResistanceAIDS Research and Human Retroviruses, 1999
- Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp.Journal of Antimicrobial Chemotherapy, 1998
- Resistance to HIV protease inhibitorsHaemophilia, 1998
- Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538)AIDS, 1996
- Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitorsAntimicrobial Agents and Chemotherapy, 1995
- Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzymeJournal of the American Chemical Society, 1995
- Human Immunodeficiency Virus Type 1 Protease Inhibitors: Evaluation of Resistance Engendered by Amino Acid Substitutions in the Enzyme's Substrate Binding SiteBiochemistry, 1994
- Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compoundsJournal of Virological Methods, 1988